{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:26:40Z","timestamp":1762298800750,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,4,22]]},"abstract":"<jats:p>A 70-year-old man presented with breathlessness, cough and fever while receiving pembrolizumab for melanoma. A CT pulmonary angiogram demonstrated small bilateral upper lobe segmental pulmonary emboli with patchy ground-glass opacities and basal perilobular consolidation, in keeping with organising pneumonia. He was treated for community-acquired pneumonia and pulmonary emboli but rapidly deteriorated, with increasing hypoxia and dyspnoea. He was admitted to the intensive care unit for support with continuous positive airway pressure and high flow nasal oxygen. His clinical condition improved once he received high-dose intravenous methylprednisolone to treat pneumonitis. His treatment was continued with a weaning course of high-dose oral steroids, and he was discharged with a persistent oxygen requirement. The patient maintained a requirement for high doses of oral steroids and continued to deteriorate. He was referred to palliative care for symptom management and died a month following hospital discharge, as a result of pneumonitis due to pembrolizumab.<\/jats:p>","DOI":"10.1136\/bcr-2018-224485","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T09:13:39Z","timestamp":1525684419000},"page":"bcr-2018-224485","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab"],"prefix":"10.1136","volume":"2018","author":[{"given":"Frances","family":"Rickard","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Hyams","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T","family":"Low","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.1","unstructured":"National Institute for Care and Health Excellence. Pembrolizumab for advanced melanoma not previously treated with ipilimumab. Technology appraisal guidance [TA366], 2015."},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.3","first-page":"1223","article-title":"Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab in 411 patients with melanoma","volume":"27","author":"Ribas","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-016-0543-x","article-title":"Pembrolizumab: A Review in Advanced Melanoma","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.6","unstructured":"National Institute for Care and Health Excellence. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. Technology appraisal guidance [TA428], 2017."},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.7","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. Technology appraisal guidance [TA447], 2017."},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.2017.35.6_suppl.284","article-title":"Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population","volume":"35","author":"Balar","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.9","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.10","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.jtho.2016.11.242","article-title":"OA03.06 Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell\u00a0Lung Cancer (NSCLC)","volume":"12","author":"Pillai","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.11","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00081-2016"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1183\/09031936.93.06040477","article-title":"Density of phenotypic markers on BAL T-lymphocytes in hypersensitivity pneumonitis, pulmonary sarcoidosis and bronchiolitis obliterans with organizing pneumonia","volume":"6","author":"Satake","year":"1993","journal-title":"Eur Respir J"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CCO.0000000000000291","article-title":"Immune-mediated respiratory adverse events of checkpoint inhibitors","volume":"28","author":"Tabchi","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505197"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0102"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"2025082723114848000_2018.may05_1.bcr-2018-224485.21","doi-asserted-by":"crossref","first-page":"mdv383","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-224485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:11:59Z","timestamp":1756361519000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-224485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":21,"alternative-id":["10.1136\/bcr-2018-224485"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-224485","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,5,7]]}}}